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Clinics and pathology 
Disease 
Rare recurrent chromosomal aberration, exclusively 
detected in B-cell lymphoproliferative disorders. 
Phenotype/cell stem origin 
B lymphocyte. 
Epidemiology 
Originally reported to be associated with a low-grade 
mature B-cell phenotype with plasmacytoid 
differentiation such as lymphoplasmacytic lymphoma, 
multiple myeloma/ plasma cell leukemia and chronic 
lymphocytic leukemia. However, the relatively 
frequent occurrence in diffuse large B-cell lymphoma, 
with or without a preceding faze of a low-grade 
lymphoma, suggests that this chromosomal aberration 
has a much wider clinical spectrum or is associated 
with disease progression. In addition, the 
t(9;14)(p13;q32) has been described occasionally in 
follicular lymphoma, mantle cell lymphoma and 
splenic marginal zone lymphoma. 
Prognosis 
No prognostic relevance has been attributed to the 
presence of the t(9;14)(p13;q32). 
Cytogenetics 
Cytogenetics morphological 
The t(9;14)(p13;q32) is readily recognisable with G- as 
well as R-banding. The presence of complex 
chromosomal aberrations, however, can mask the 
presence of this rearrangement. 
Probes 
Probes used for detection of PAX5 rearrangements 
include PAX5 spanning probes (RP11-12P15, RP11-
344B23 and RP11-297B17) and a probe extending 
approximately up to 200 kb upstream of PAX5, RP11-
220I1. IgH rearrangements can be demonstrated using a 
commercially available dual colour probe, or IgH 
probes, RP11-47P23 and RP5- 
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Dual and triple colour hybridisations demonstrating the presence of a t(9;14)(p13;q32) resulting in PAX5/IGH rearrangement. A,B: partial 
metaphase and interphase nucleus cohybridized with PAX5 locus specific probes (yellow) and dual colour interphaze cytogenetics using 
IgH flanking probes (red) and PAX5 locus specific probes. 
 
998D24, mapping to the IgH constant and variable 
regions, respectively. 
Additional anomalies 
No recurrent additional aberrations have been 
described. However, the majority of t(9;14)(p13;q32) 
have been reported in addition to complex 
chromosomal aberrations. 
Variants 
In addition to the t(9;14)(p13;q32), other translocations 
presumably involving the immunoglobulin light chain 
genes and PAX5 have been reported, such as the 
t(2;9)(p12;p13) and the t(9;22)(p13;q11). 
Genes involved and proteins 
IgH 
Location 
14q32 
PAX5 
Location 
9p13 
DNA/RNA 
The PAX5 coding region extends over a genomic 
interval of approximately 200 kb and comprises 10 
exons. Two alternative transcripts have been identified, 
originating from alternative promotor usage, containing 
exon 1A or 1B. Full length mRNA is 3650 bp. 
Protein 
PAX5 belongs to the paired box family of transcription 
factors, involved in a multitude of developmental 
processes. PAX5 was originally identified as a B-cell 
specific transcription factor (hence its original name, 
BSAP). Recently it has been shown that PAX5 
expression is continuously required in B cell lineage 
commitment during early B cell development. 
 
Result of the chromosomal 
anomaly 
Hybrid gene 
Description 
Translocation of the entire PAX5 gene to chromosome 
14. The breakpoints at 9p13 are heterogeneous and can 
reside up to 200kb upstream (i.e. centromeric) of 
PAX5. 
Detection 
The variability of the chromosomal breakpoints at 9p13 
as well 14q32 precludes genomic PCR approaches for 
detection of IgH PAX5 juxtaposition. In addition, the 
expression pattern of PAX5 hampers RT-PCR methods 
for demonstrating elevated PAX5 expression in B-cell 
proliferations with suspected or proven PAX5 
rearrangement. Currently, the only methods for 
detecting IgH PAX5 juxtaposition reliably include 
conventional and molecular cytogenetics. 
Fusion protein 
Description 
In analogy to other 14q32 rearrangements, no fusion 
gene is created by the translocation. Rather, the 
genomic rearrangement leads to forced PAX5 
expression. 
Oncogenesis 
In contrast to the novel insights in the role of PAX5 in 
B-cell lineage commitment, little is know on the role of 
PAX5 in the malignant transformation of B cells. The 
recent demonstration of PAX5 hypermutation in diffuse 
large-cell lymphomas, in addition to PAX5 
overexpression associated with the t(9;14), suggest that 
PAX5 acts as a dominant oncogene. 
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